Top

Published in:

Open Access 10-05-2022 | Cardiomyopathy

Clinical application of CMR in cardiomyopathies: evolving concepts and techniques

A position paper of myocardial and pericardial diseases and cardiac magnetic resonance working groups of Italian society of cardiology

Authors: Marco Merlo, Giulia Gagno, Anna Baritussio, Barbara Bauce, Elena Biagini, Marco Canepa, Alberto Cipriani, Silvia Castelletti, Santo Dellegrottaglie, Andrea Igoren Guaricci, Massimo Imazio, Giuseppe Limongelli, Maria Beatrice Musumeci, Vanda Parisi, Silvia Pica, Gianluca Pontone, Giancarlo Todiere, Camilla Torlasco, Cristina Basso, Gianfranco Sinagra, Pasquale Perrone Filardi, Ciro Indolfi, Camillo Autore, Andrea Barison

Published in: Heart Failure Reviews | Issue 1/2023

Abstract

Cardiac magnetic resonance (CMR) has become an essential tool for the evaluation of patients affected or at risk of developing cardiomyopathies (CMPs). In fact, CMR not only provides precise data on cardiac volumes, wall thickness, mass and systolic function but it also a non-invasive characterization of myocardial tissue, thus helping the early diagnosis and the precise phenotyping of the different CMPs, which is essential for early and individualized treatment of patients. Furthermore, several CMR characteristics, such as the presence of extensive LGE or abnormal mapping values, are emerging as prognostic markers, therefore helping to define patients’ risk. Lastly new experimental CMR techniques are under investigation and might contribute to widen our knowledge in the field of CMPs. In this perspective, CMR appears an essential tool to be systematically applied in the diagnostic and prognostic work-up of CMPs in clinical practice. This review provides a deep overview of clinical applicability of standard and emerging CMR techniques in the management of CMPs.

Available only for authorised users

Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al (2007) Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 29(2):270–276CrossRef

Merlo M, Cannatà A, Pio Loco C, Stolfo D, Barbati G, Artico J et al (2020) Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 22(7):1111–1121CrossRef

Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E (2020) Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 22(1):17CrossRef

Francone M, Aquaro GD, Barison A, Castelletti S, de Cobelli F, de Lazzari M et al (2021) Appropriate use criteria for cardiovascular MRI: SIC – SIRM position paper Part 2 (myocarditis, pericardial disease, cardiomyopathies and valvular heart disease). J Cardiovasc Med 22(7):515–529CrossRef

Pontone G, Di Cesare E, Castelletti S, De Cobelli F, De Lazzari M, Esposito A et al (2021) Appropriate use criteria for cardiovascular magnetic resonance imaging (CMR): SIC—SIRM position paper part 1 (ischemic and congenital heart diseases, cardio-oncology, cardiac masses and heart transplant). Radiol med 126(3):365–379CrossRef

Aquaro GD, Camastra G, Monti L, Lombardi M, Pepe A, Castelletti S et al (2017) Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study: Reference Range of Normality for CMR. J Magn Reson Imaging 45(4):1055–1067CrossRef

Aquaro GD, Nucifora G, Pederzoli L, Strata E, De Marchi D, Todiere G et al (2012) Fat in left ventricular myocardium assessed by steady-state free precession pulse sequences. Int J Cardiovasc Imaging 28(4):813–821CrossRef

Ferreira PF, Gatehouse PD, Mohiaddin RH, Firmin DN (2013) Cardiovascular magnetic resonance artefacts. J Cardiovasc Magn Reson 15(1):41CrossRef

Barison A, Baritussio A, Cipriani A, De Lazzari M, Aquaro GD, Guaricci AI et al (2021) Cardiovascular magnetic resonance: What clinicians should know about safety and contraindications. Int J Cardiol 331:322–328CrossRef

10.

Greulich S, Ferreira VM, Dall’Armellina E, Mahrholdt H (2015) Myocardial Inflammation—Are We There Yet? Curr Cardiovasc Imaging Rep 8(3):6

11.

Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M (2016) T1 Mapping. J Am Cardiol Img 9(1):67–81

12.

Bulluck H, Maestrini V, Rosmini S, Abdel-Gadir A, Treibel TA, Castelletti S et al (2015) Myocardial T1 Mapping: – Hope or Hype? –. Circ J 79(3):487–494CrossRef

13.

Radenkovic D, Weingärtner S, Ricketts L, Moon JC, Captur G (2017) T1 mapping in cardiac MRI. Heart Fail Rev 22(4):415–430CrossRef

14.

Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G et al (2012) Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 98(19):1436–1441CrossRef

15.

Ugander M, Oki AJ, Hsu L-Y, Kellman P, Greiser A, Aletras AH et al (2012) Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 33(10):1268–1278CrossRef

16.

Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP et al (2011) Direct T2 Quantification of Myocardial Edema in Acute Ischemic Injury. J Am Cardiol Img 4(3):269–78

17.

Lota AS, Gatehouse PD, Mohiaddin RH (2017) T2 mapping and T2* imaging in heart failure. Heart Fail Rev 22(4):431–440CrossRef

18.

Positano V, Meloni A, Santarelli MF, Gerardi C, Bitti PP, Cirotto C et al (2015) Fast generation of T2⁎ maps in the entire range of clinical interest: Application to thalassemia major patients. Comput Biol Med 56:200–210CrossRef

19.

McNally EM, Mestroni L (2017) Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res 121(7):731–748CrossRef

20.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726CrossRef

21.

Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C (2019) European Association of Cardiovascular Imaging expert consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. Eur Heart J Cardiovasc Imaging 20(12):1321–1331CrossRef

22.

Patel AR, Kramer CM (2017) Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy. J Am Cardiol Img 10(10):1180–93

23.

Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA et al (2015) Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging 16(1):14–22CrossRef

24.

Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA et al (2017) Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy. J Heart Failure. 5(1):28–38

25.

Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M et al (2006) Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. J Am Coll Cardiol 48(10):1977–1985CrossRef

26.

Pontone G, Guaricci AI, Andreini D, Solbiati A, Guglielmo M, Mushtaq S et al (2016) Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter–Defibrillator Therapy. Circ: Cardiovasc Imaging [Internet]. 2016 Oct [cited 2021 Nov 4];9(10). Available from: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.115.004956

27.

Guaricci AI, Masci PG, Lorenzoni V, Schwitter J, Pontone G (2019) DERIVATE Study Group, 4327 Results of the DERIVATE study in non-ischemic dilated cardiomyopathy (NICM), European Heart J 40(Issue Supplement_1, October 2019):ehz745.0164

28.

Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F et al (2011) Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 13(1):29CrossRef

29.

Barison A, Aimo A, Ortalda A, Todiere G, Grigoratos C, Passino C et al (2018) Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol 250:195–200CrossRef

30.

Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M et al (2017) Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation 135(22):2106–2115CrossRef

31.

Puntmann VO, Carr-White G, Jabbour A, Yu C-Y, Gebker R, Kelle S et al (2016) T1-Mapping and Outcome in Nonischemic Cardiomyopathy. J Am Cardiol Img 9(1):40–50

32.

Barison A, Del Torto A, Chiappino S, Aquaro GD, Todiere G, Vergaro G et al (2015) Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. J Cardiovasc Med 16(10):681CrossRef

33.

Vita T, Gräni C, Abbasi SA, Neilan TG, Rowin E, Kaneko K et al (2019) Comparing CMR Mapping Methods and Myocardial Patterns Toward Heart Failure Outcomes in Nonischemic Dilated Cardiomyopathy. J Am Cardiol Img (8):1659–69

34.

Gulati A, Ismail TF, Jabbour A, Alpendurada F, Guha K, Ismail NA et al (2013) The Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Nonischemic Dilated Cardiomyopathy. Circulation 128(15):1623–1633CrossRef

35.

Buss SJ, Breuninger K, Lehrke S, Voss A, Galuschky C, Lossnitzer D et al (2015) Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging 16(3):307–315CrossRef

36.

Farzaneh-Far A, Romano S (2020) Imaging and Impact of Myocardial Strain in Myocarditis. J Am Cardiol Img (9):1902–1905

37.

Corrado D, Basso C, Judge DP (2017) Arrhythmogenic Cardiomyopathy. Circ Res 121(7):784–802CrossRef

38.

Corrado D, Zorzi A, Cipriani A, Bauce B, Bariani R, Beffagna G et al (2021) Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy. JAHA [Internet]. 2021 Sep 21 [cited 2021 Nov 5];10(18). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.121.021987

39.

Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari MD et al (2020) Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol 319:106–114CrossRef

40.

Kellman P, Hernando D, Shah S, Zuehlsdorff S, Jerecic R, Mancini C et al (2009) Multiecho dixon fat and water separation method for detecting fibrofatty infiltration in the myocardium: Fibrofatty Infiltration in Myocardium. Magn Reson Med 61(1):215–221CrossRef

41.

Tandri H, Castillo E, Ferrari VA, Nasir K, Dalal D, Bomma C et al (2006) Magnetic Resonance Imaging of Arrhythmogenic Right Ventricular Dysplasia. J Am Coll Cardiol 48(11):2277–2284CrossRef

42.

Cipriani A, Bauce B, De Lazzari M, Rigato I, Bariani R, Meneghin S et al (2020) Arrhythmogenic Right Ventricular Cardiomyopathy: Characterization of Left Ventricular Phenotype and Differential Diagnosis With Dilated Cardiomyopathy. JAHA [Internet]. 2020 Mar 3 [cited 2021 Nov 5];9(5). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.119.014628

43.

Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B et al (2021) ‘Hot phase’ clinical presentation in arrhythmogenic cardiomyopathy. EP Europace 23(6):907–917CrossRef

44.

Aquaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N et al (2020) Prognostic Value of Magnetic Resonance Phenotype in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. J Am Coll Cardiol 75(22):2753–2765CrossRef

45.

Pfluger HB, Phrommintikul A, Mariani JA, Cherayath JG, Taylor AJ (2008) Utility of myocardial fibrosis and fatty infiltration detected by cardiac magnetic resonance imaging in the diagnosis of arrhythmogenic right ventricular dysplasia–a single centre experience. Heart Lung Circ 17(6):478–483CrossRef

46.

Augusto JB, Eiros R, Nakou E, Moura-Ferreira S, Treibel TA, Captur G et al (2019) Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. European Heart J - Cardiol Img jez188

47.

Castelletti S, Vischer AS, Syrris P, Crotti L, Spazzolini C, Ghidoni A et al (2017) Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. Int J Cardiol 249:268–273CrossRef

48.

Muscogiuri G, Fusini L, Ricci F, Sicuso R, Guglielmo M, Baggiano A et al (2021) Additional diagnostic value of cardiac magnetic resonance feature tracking in patients with biopsy-proven arrhythmogenic cardiomyopathy. Int J Cardiol 339:203–210CrossRef

49.

Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bartunek J et al (2016) Myocarditis in Clinical Practice. Mayo Clin Proc 91(9):1256–1266CrossRef

50.

Seferović PM, Tsutsui H, McNamara DM, Ristić AD, Basso C, Bozkurt B et al (2021) Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail 23(6):854–871CrossRef

51.

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT et al (2009) Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper. J Am Coll Cardiol 53(17):1475–1487CrossRef

52.

Francone M, Chimenti C, Galea N, Scopelliti F, Verardo R, Galea R et al (2014) CMR Sensitivity Varies With Clinical Presentation and Extent of Cell Necrosis in Biopsy-Proven Acute Myocarditis. J Am Cardiol Img 7(3):254–63

53.

Gannon MP, Schaub E, Grines CL, Saba SG (2019) State of the art: Evaluation and prognostication of myocarditis using cardiac MRI. J Magn Reson Imaging 49(7):e122–e131CrossRef

54.

Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U et al (2018) Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation. J Am Coll Cardiol 72(24):3158–3176CrossRef

55.

Kotanidis CP, Bazmpani M-A, Haidich A-B, Karvounis C, Antoniades C, Karamitsos TD (2018) Diagnostic Accuracy of Cardiovascular Magnetic Resonance in Acute Myocarditis. J Am Cardiol Img 11(11):1583–90

56.

Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19(1):75CrossRef

57.

Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe A, Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra M, Barison A, Di Bella G (2017) Cardiac Magnetic Resonance Working Group of the Italian Society of Cardiology. Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function: ITAMY Study. J Am Coll Cardiol 70(16):1977–1987

58.

Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K et al (2017) Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol 70(16):1964–1976CrossRef

59.

Baeßler B, Treutlein M, Schaarschmidt F, Stehning C, Schnackenburg B, Michels G et al (2017) A novel multiparametric imaging approach to acute myocarditis using T2-mapping and CMR feature tracking. J Cardiovasc Magn Reson 19(1):71CrossRef

60.

Porcari A, Merlo M, Crosera L, Stolfo D, Barbati G, Biondi F et al (2020) Strain analysis reveals subtle systolic dysfunction in confirmed and suspected myocarditis with normal LVEF. A cardiac magnetic resonance study. Clin Res Cardiol 109(7):869–80

61.

Fischer K, Obrist SJ, Erne SA, Stark AW, Marggraf M, Kaneko K et al (2020) Feature Tracking Myocardial Strain Incrementally Improves Prognostication in Myocarditis Beyond Traditional CMR Imaging Features. J Am Cardiol Img 13(9):1891–901

62.

Clinical Course and Management of Hypertrophic Cardiomyopathy (2018) N Engl J Med 379(20):1976–1977CrossRef

63.

Pontone G, Di Bella G, Castelletti S, Maestrini V, Festa P, Ait-Ali L et al (2017) Clinical recommendations of cardiac magnetic resonance, Part II: inflammatory and congenital heart disease, cardiomyopathies and cardiac tumors. J Cardiovasc Med 18(4):209–222CrossRef

64.

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 76(25):e159-240CrossRef

65.

Quarta G, Aquaro GD, Pedrotti P, Pontone G, Dellegrottaglie S, Iacovoni A et al (2018) Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. Eur Heart J Cardiovasc Imaging 19(6):601–610CrossRef

66.

Kozor R, Nordin S, Treibel TA, Rosmini S, Castelletti S, Fontana M, Captur G, Baig S, Steeds RP, Hughes D, Manisty C, Grieve SM, Figtree GA, Moon JC (2017) Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping. Eur Heart J Cardiovasc Imaging 18(9):1034–1040CrossRef

67.

Reant P, Captur G, Mirabel M, Nasis A, M. Sado D, Maestrini V et al (2015) Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 17(1):64

68.

Todiere G, Aquaro GD, Piaggi P, Formisano F, Barison A, Masci PG et al (2012) Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 60(10):922–929CrossRef

69.

Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR et al (2008) Significance of Papillary Muscle Abnormalities Identified by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. Am J Cardiol 101(5):668–673CrossRef

70.

Captur G, Lopes LR, Mohun TJ, Patel V, Li C, Bassett P et al (2014) Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 7(6):863–871CrossRef

71.

Kato S, Nakamori S, Bellm S, Jang J, Basha T, Maron M et al (2016) Myocardial Native T1 Time in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 118(7):1057–1062CrossRef

72.

Treibel TA, Kozor R, Menacho K, Castelletti S, Bulluck H, Rosmini S et al (2017) Left Ventricular Hypertrophy Revisited: Cell and Matrix Expansion Have Disease-Specific Relationships. Circulation 136(25):2519–2521CrossRef

73.

Maron MS, Rowin EJ, Maron BJ (2017) How to Image Hypertrophic Cardiomyopathy. Circ: Cardiovascular Imaging [Internet]. 2017 Jul [cited 2021 Nov 6];10(7). Available from: https://www.ahajournals.org/doi/ 10.1161/CIRCIMAGING.116.005372

74.

Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43(12):2260–2264CrossRef

75.

Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M et al (2009) Cardiac Magnetic Resonance Detection of Myocardial Scarring in Hypertrophic Cardiomyopathy. J Am Coll Cardiol 54(3):242–249CrossRef

76.

Aquaro GD, Masci P, Formisano F, Barison A, Strata E, Pingitore A et al (2010) Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity. Am J Cardiol 105(3):392–397CrossRef

77.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T et al (2014) Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation 130(6):484–495CrossRef

78.

Todiere G, Nugara C, Gentile G, Negri F, Bianco F, Falletta C et al (2019) Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score. Am J Cardiol 124(8):1286–1292CrossRef

79.

Freitas P, Ferreira AM, Arteaga-Fernández E, de Oliveira AM, Mesquita J, Abecasis J et al (2019) The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson 21(1):50CrossRef

80.

Hen Y, Takara A, Iguchi N, Utanohara Y, Teraoka K, Takada K et al (2018) High Signal Intensity on T2-Weighted Cardiovascular Magnetic Resonance Imaging Predicts Life-Threatening Arrhythmic Events in Hypertrophic Cardiomyopathy Patients. Circ J 82(4):1062–1069CrossRef

81.

Castelletti S, Menacho K, Davies RH, Maestrini V, Treibel TA, Rosmini S et al (2021) Hypertrophic cardiomyopathy: insights from extracellular volume mapping. European J Prevent Cardiol zwaa083

82.

Ariga R, Tunnicliffe EM, Manohar SG, Mahmod M, Raman B, Piechnik SK et al (2019) Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias. J Am Coll Cardiol 73(20):2493–2502CrossRef

83.

Zhang Q, Burrage MK, Lukaschuk E, Shanmuganathan M, Popescu IA, Nikolaidou C et al (2021) Toward Replacing Late Gadolinium Enhancement With Artificial Intelligence Virtual Native Enhancement for Gadolinium-Free Cardiovascular Magnetic Resonance Tissue Characterization in Hypertrophic Cardiomyopathy. Circulation 144(8):589–599CrossRef

84.

Aquaro GD, Grigoratos C, Bracco A, Proclemer A, Todiere G, Martini N et al (2020) Late Gadolinium Enhancement–Dispersion Mapping: A New Magnetic Resonance Imaging Technique to Assess Prognosis in Patients With Hypertrophic Cardiomyopathy and Low-Intermediate 5-Year Risk of Sudden Death. Circ: Cardiovascular Imaging [Internet]. 2020 Jun [cited 2021 Nov 6];13(6). Available from: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.120.010489

85.

Sánchez-Somonte P, Quinto L, Garre P, Zaraket F, Alarcón F, Borràs R et al (2021) Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm 18(8):1336–1343CrossRef

86.

Schofield R, Ganeshan B, Fontana M, Nasis A, Castelletti S, Rosmini S et al (2019) Texture analysis of cardiovascular magnetic resonance cine images differentiates aetiologies of left ventricular hypertrophy. Clin Radiol 74(2):140–149CrossRef

87.

Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ et al (2020) Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2020 Jul 7 [cited 2021 Nov 6];142(1). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792

88.

Dorbala S, Cuddy S, Falk RH (2020) How to Image Cardiac Amyloidosis. J Am Cardiol Img 13(6):1368–83

89.

Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K et al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110(4):479–506CrossRef

90.

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42(16):1554–1568CrossRef

91.

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM et al (2015) Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation 132(16):1570–1579CrossRef

92.

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS et al (2017) Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol 70(4):466–477CrossRef

93.

Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD et al (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3(2):155–164CrossRef

94.

Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK et al (2020) Native T1 Mapping in Transthyretin Amyloidosis. J Am Cardiol Img (2):157–65

95.

Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T et al (2020) Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. J Am Cardiol Img 13(1 Pt 1):69–80

96.

Pan JA, Kerwin MJ, Salerno M (2020) Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis. J Am Cardiol Img 13(6):1299–310

97.

Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S et al (2008) Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. J Am Coll Cardiol 51(10):1022–1030CrossRef

98.

Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S et al (2018) CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. J Am Cardiol Img 11(1):152–4

99.

Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ et al (2021) Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. J Am Cardiol Img 14(1):189–99

100.

Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A et al (2018) Myocardial Edema and Prognosis in Amyloidosis. J Am Coll Cardiol 71(25):2919–2931CrossRef

101.

Chacko L, Kotecha T, Martinez-Naharro A, Brown J, Knight D, Steriotis A et al (2019) 1171Myocardial perfusion mapping in cardiac amyloidosis - exploring the spectrum from infiltration to ischaemia. European Heart J 40(Supplement_1):ehz748.0013

102.

Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442–1448CrossRef

103.

Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M et al (2014) Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis. Circulation 129(18):1840–1849CrossRef

104.

Mohty D, Boulogne C, Magne J, Varroud-Vial N, Martin S, Ettaif H et al (2016) Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study. Eur Heart J Cardiovasc Imaging 17(9):961–969CrossRef

105.

Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH et al (2017) Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 18(10):1128–1137

106.

Di Toro A, Favalli V, Arbustini E (2018) Anderson-Fabry disease. J Cardiovasc Med 19:e1-5CrossRef

107.

Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C et al (2016) Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart 102(4):298–302CrossRef

108.

Moon J (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24(23):2151–2155CrossRef

109.

Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M et al (2011) Differences in Fabry Cardiomyopathy Between Female and Male Patients. J Am Cardiol Img 4(6):592–601

110.

Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G et al (2013) Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. Circ Cardiovasc Imaging 6(3):392–398CrossRef

111.

Perry R, Shah R, Saiedi M, Patil S, Ganesan A, Linhart A et al (2019) The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease. JACC Cardiovasc Imaging 12(7 Pt 1):1230–1242CrossRef

112.

Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A et al (2016) Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy. J Am Coll Cardiol 68(15):1707–1708CrossRef

113.

Augusto JB, Nordin S, Vijapurapu R, Baig S, Bulluck H, Castelletti S et al (2020) Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease. Circ: Cardiovasc Imaging [Internet]. 2020 Mar [cited 2021 Nov 29];13(3). Available from: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.119.010171

114.

Azevedo O, Cordeiro F, Gago MF, Miltenberger-Miltenyi G, Ferreira C, Sousa N et al (2021) Fabry Disease and the Heart: A Comprehensive Review. IJMS 22(9):4434CrossRef

115.

Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH et al (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22(23):2171–2179CrossRef

116.

Sado DM, Maestrini V, Piechnik SK, Banypersad SM, White SK, Flett AS et al (2015) Noncontrast myocardial T ₁ mapping using cardiovascular magnetic resonance for iron overload: Myocardial T ₁ in Iron Overload. J Magn Reson Imaging 41(6):1505–1511CrossRef

117.

Wei X, Zhao L, Xie J, Liu Y, Du Z, Zhong X et al (2021) Cardiac Phenotype Characterization at MRI in Patients with Danon Disease: A Retrospective Multicenter Case Series. Radiology 299(2):303–310CrossRef

118.

Towbin JA, Lorts A, Jefferies JL (2015) Left ventricular non-compaction cardiomyopathy. The Lancet 386(9995):813–825CrossRef

119.

Arbustini E, Favalli V, Narula N, Serio A, Grasso M (2016) Left Ventricular Noncompaction: A Distinct Genetic Cardiomyopathy? J Am Coll Cardiol 68(9):949–966CrossRef

120.

van Waning JI, Caliskan K, Hoedemaekers YM, van Spaendonck-Zwarts KY, Baas AF, Boekholdt SM et al (2018) Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. J Am Coll Cardiol 71(7):711–722CrossRef

121.

Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH et al (2005) Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 46(1):101–105CrossRef

122.

Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert J-Y et al (2010) Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 31(9):1098–1104CrossRef

123.

Weir-McCall JR, Yeap PM, Papagiorcopulo C, Fitzgerald K, Gandy SJ, Lambert M et al (2016) Left Ventricular Noncompaction. J Am Coll Cardiol 68(20):2157–2165CrossRef

124.

Zemrak F, Ahlman MA, Captur G, Mohiddin SA, Kawel-Boehm N, Prince MR et al (2014) The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study. J Am Coll Cardiol 64(19):1971–80

125.

Grigoratos C, Barison A, Ivanov A, Andreini D, Amzulescu M-S, Mazurkiewicz L et al (2019) Meta-Analysis of the Prognostic Role of Late Gadolinium Enhancement and Global Systolic Impairment in Left Ventricular Noncompaction. J Am Cardiol Img 12(11):2141–51

126.

Casas G, Limeres J, Oristrell G, Gutierrez-Garcia L, Andreini D, Borregan M et al (2021) Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction. J Am Coll Cardiol 78(7):643–662CrossRef

127.

Guaricci AI, Masci PG, Muscogiuri G, Guglielmo M, Baggiano A, Fusini L et al (2021) CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: an international Registry. EP Europace 23(7):1072–1083CrossRef

128.

Andreini D, Pontone G, Bogaert J, Roghi A, Barison A, Schwitter J et al (2016) Long-Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle Noncompaction. J Am Coll Cardiol 68(20):2166–2181CrossRef

129.

Vidula MK, Bravo PE (2021) Multimodality imaging for the diagnosis of infiltrative cardiomyopathies. Heart heartjnl-2020–318001

130.

Genovesi D, Vergaro G, Giorgetti A, Marzullo P, Scipioni M, Santarelli MF et al (2021) [18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions. J Am Cardiol Img 14(1):246–55

Title: Clinical application of CMR in cardiomyopathies: evolving concepts and techniques
A position paper of myocardial and pericardial diseases and cardiac magnetic resonance working groups of Italian society of cardiology
Authors: Marco Merlo
Giulia Gagno
Anna Baritussio
Barbara Bauce
Elena Biagini
Marco Canepa
Alberto Cipriani
Silvia Castelletti
Santo Dellegrottaglie
Andrea Igoren Guaricci
Massimo Imazio
Giuseppe Limongelli
Maria Beatrice Musumeci
Vanda Parisi
Silvia Pica
Gianluca Pontone
Giancarlo Todiere
Camilla Torlasco
Cristina Basso
Gianfranco Sinagra
Pasquale Perrone Filardi
Ciro Indolfi
Camillo Autore
Andrea Barison
Publication date: 10-05-2022
Publisher: Springer US
Keywords: Cardiomyopathy
Cardiac Amyloidosis
Published in: Heart Failure Reviews / Issue 1/2023
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-022-10235-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical application of CMR in cardiomyopathies: evolving concepts and techniques

A position paper of myocardial and pericardial diseases and cardiac magnetic resonance working groups of Italian society of cardiology

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Rate adaptive pacing in people with chronic heart failure increases peak heart rate but not peak exercise capacity: a systematic review

Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure

Fibroblast growth factor 21 in heart failure

Combined pre- and post-capillary pulmonary hypertension in left heart disease

Transition to heart transplantation in post-myocardial infarction ventricular septal rupture: a systematic review

The value of myocardial strain imaging in the evaluation of patients with repaired Tetralogy of Fallot: a review of the literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page